The US District Court for the Northern District of California has found that diagnostic claims covering conventional detection methods do not make the use of a natural phenomenon patent eligible.
A US trademark for Botulex would be too confusingly similar to Botox if granted, the Trademark Trial and Appeal Board has ruled.
The US Court of Appeals for the Federal Circuit affirmed on Tuesday that pharmaceutical company Pfizer can patent a DNA polynucleotide ahead of rival Sanofi-Aventis.
Novartis has urged the FDA to allow biosimilars to bear the same international nonproprietary names as their reference products.
The Indian Patent Office has rejected an application for a compulsory licence that was filed by domestic drug maker BDR Pharmaceuticals.
Europe’s highest court has said supplementary protection certificates for plant protection products cannot be granted after the same product has been authorised on emergency grounds.
A US company has filed a lawsuit against global healthcare company GE Healthcare , alleging it has infringed its patented microscope technology.
A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.
The governor of California, Jerry Brown, has refused to sign legislation seeking to introduce changes to the state’s pharmacy law on biosimilars.
Mr Justice Arnold has refused to recuse himself from a patent trial after he was accused of being conflicted by an expert witness.